Table 4 Deterministic results per therapy arm
From: Economic evaluation of trimetazidine in the management of chronic stable angina in Greece
TMZ 70 mg/d + SoC | SoC alone | Incremental | |
|---|---|---|---|
Costs | |||
Total cost (€) | 1755.57 | 1751.76 | 3.82 |
Drug acquisition cost (€) | 341.36 | 273.61 | 67.75 |
Hospitalization cost (€) | 293.63 | 320.72 | −27.09 |
Outpatient visits cost (€) | 26.89 | 28.28 | −1.39 |
Vascular interventions cost (€) | 990.01 | 1022.87 | −32.87 |
Diagnostic tests cost (€) | 71.22 | 72.93 | −1.71 |
Laboratory tests cost (€) | 32.47 | 33.35 | −0.88 |
Health Outcomes | |||
QALYs | 0.6650 | 0.6562 | 0.0088 |
LYs | 0.9747 | 0.9743 | 0.0004 |
Incremental analysis | |||
ICER per QALY (€) | 430.67 | ||